In a 2005 pilot study, a proprietary tablet (Super Malic) containing 200 mg of malic acid and 50 mg of magnesium was tested as a treatment of primary fibromyalgia syndrome (FM). Twenty-four sequential patients with primary FM were randomized to a fixed dose (3 tablets bid), placebo controlled, 4-week/course, pilot trial followed by a 6-month, open label, dose escalation (up to 6 tablets bid) trial. With dose escalation and a longer duration of treatment in the open label trial (up to six tablets twice a day for six months), significant reductions in the severity of all 3 primary pain/tenderness measures were obtained without limiting risks.
Russell, I. J., Michalek, J. E., Flechas, J. D., & Abraham, G. E. (1995). Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. The Journal of rheumatology, 22(5), 953–958.